What is amycretin?
A beginner-friendly introduction to amycretin: Novo Nordisk's investigational single-molecule GLP-1 and amylin co-agonist, built in both an oral tablet and a weekly injection, and why its striking early numbers are only early signals.
Two hormones in one molecule
Amycretin is an experimental obesity and diabetes drug from Novo Nordisk, engineered as a single peptide that copies two natural appetite hormones at once: GLP-1 (the hormone behind Ozempic and Wegovy) and amylin (a second fullness hormone from the pancreas).
It is unusual for coming in both a daily tablet and a weekly injection. This unit sets the honest foundation: what amycretin actually is, how it differs from combining two separate drugs, and what "investigational" means for a molecule that is still in its earliest human trials and cannot be legally bought.
What you'll learn
- What amycretin is, and why one molecule activating two receptors is different from CagriSema
- How the GLP-1 and amylin arms combine to control appetite, the stomach, and glucose
- What the two Lancet 2025 early-phase trials and the 2026 phase 2 readout actually showed, and why the numbers are early signals
- Its investigational status, the safety profile, and the honest limits of an early-phase dataset
What this course covers
12 units take you from the essentials to an in-depth understanding.
- 01 What is amycretin? Two hormones in one molecule free
- 02 The two parent hormones The satiety hormone and the incretin paid
- 03 One molecule, two receptors The single-molecule strategy paid
- 04 How amycretin works Two arms, one brainstem target paid
- 05 Chemistry & pharmacokinetics A 68-amino-acid fusion, engineered to last paid
- 06 The oral peptide problem How a peptide becomes a pill, and what nobody has published paid
- 07 The human trials What the human data actually shows paid
- 08 The obesity drug landscape Where amycretin sits in a crowded field paid
- 09 Safety & Side Effects Mostly the gut, with class questions to watch paid
- 10 Dosing & Administration The trial schedules, and why you cannot buy it paid
- 11 Regulatory & market landscape A drug the market is watching, not yet selling paid
- 12 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam
Key terms
What amycretin actually is
Amycretin is a single engineered peptide that activates two appetite systems at once. One half mimics GLP-1, the gut hormone behind today's blockbuster weight-loss drugs; the other half mimics amylin, a fullness hormone your pancreas releases with insulin after meals. Fusing both jobs into one molecule is the entire idea.
The name itself is a blend: amylin plus incretin. Novo Nordisk gave it the development code NNC0487-0111 and later the international nonproprietary name zenagamtide, which is the name to search when you look up trial registrations and 2026 conference readouts. Unusually, it was built in two forms at once: a once-daily tablet and a once-weekly injection. Both are the same molecule, just delivered differently, which is a theme this course returns to.
Think of amycretin as "two appetite hormones welded into one peptide." It borrows GLP-1 and amylin and delivers both from a single molecule.
AdvancedWhy "one molecule" is the whole point
The obesity field already knows that combining GLP-1 with a second hormone beats GLP-1 alone. The usual way is to co-administer two separate drugs. Amycretin's bet is that a single peptide doing both jobs is simpler to manufacture, can be made into a pill, and needs only one dose. That elegance is real, but it also fixes the balance between the two arms at the molecular level, a trade-off later units unpack.
One molecule, not two drugs
The most common confusion is between amycretin and CagriSema. Both engage the same two hormone systems (GLP-1 and amylin), so people assume they are the same thing. They are not: CagriSema is two separate peptides mixed together, while amycretin is one peptide doing both jobs.
This distinction matters more than it sounds. Because amycretin is unimolecular, you cannot turn one arm up and the other down; the ratio is baked into the molecule. A two-drug combination like CagriSema keeps that flexibility. Neither approach is obviously better yet, which is exactly why both are being developed in parallel.
AdvancedWhy a fixed ratio is a genuine design gamble
With two separate drugs, a clinician could in principle push more GLP-1 for glucose control or more amylin for satiety. Amycretin locks the GLP-1-to-amylin potency ratio into the molecule, chosen once by its designers. If that ratio is close to optimal, the single-molecule simplicity wins. If different patients need different balances, the two-drug combo could prove more adaptable. Only large trials can settle which bet pays off.
A pill and an injection
Amycretin's other headline feature is that it exists as both a once-daily tablet and a once-weekly injection. Most peptide drugs are injectable only, because the gut destroys peptides and a large, water-loving peptide crosses the gut wall poorly. How amycretin's tablet gets around that is not described in any published report, so this course names the problem without inventing the solution.
Having both forms is strategically clever: an oral option competes in the race for a convenient weight-loss pill, while the weekly injection competes with the injectable heavyweights. They are the same molecule, so the difference is purely delivery, not a different drug, and each has its own separate early trial.
AdvancedWhy the oral dose is so much larger
Oral peptide delivery is inefficient as a general rule: peptides are degraded by gut enzymes and absorbed poorly across the gut wall. That general principle is why oral amycretin is dosed in tens of milligrams while the injection uses far less. What no published source states is how much of an oral amycretin dose actually reaches the blood, by any formulation. A course that quotes a bioavailability percentage here is borrowing it from a different drug.
What "investigational" means here
Amycretin is not approved by any regulator in the published record, and the sponsor says so itself in its most recent release. It is investigational: characterized in small early trials, now being tested in large ones, but not something a doctor can prescribe or that you can legally buy. That status shapes everything else in this course.
The practical upshot is stark: the only legitimate source of amycretin today is a Novo Nordisk clinical trial. A pharmacy compounding under section 503A may use a bulk substance only if it has a US Pharmacopeia or National Formulary monograph, is a component of an FDA-approved drug product, or appears on the FDA's 503A bulks list. An investigational peptide that is in none of the three meets no route, so no compounding pathway reaches it. Any "research peptide" amycretin sold online is unregulated, unverified, and impossible to authenticate.
AdvancedWhy a 68-amino-acid drug is nearly impossible to fake safely
Amycretin is a complex 68-amino-acid peptide with a site-specific fatty-acid modification. Making it correctly requires precise synthesis, folding, and purification. A gray-market vial is unverified as to identity, purity and content by every source this course uses, and a buyer has no way to check identity, purity, endotoxin level or dose. Complexity is itself a safety argument against non-trial sourcing.
The honest evidence picture
Amycretin sits in an unusual spot: it has produced striking early numbers that circulate widely online, alongside a human dataset that is genuinely tiny. Keeping those two facts together is the job of this course, and the place to start is an honest map of what is and is not established.
Hold these four tiers in mind for the rest of the course. The safety and mechanism sit on reasonably solid ground, but the headline weight-loss numbers and every long-term question sit in the weak-to-missing tiers. Honest education names that structure instead of rounding amycretin up to a finished breakthrough.
The most common mistake is treating amycretin's biggest weight-loss headline as settled efficacy. It comes from a dose-escalation arm of 17 people, and it is an estimate of what those people would have lost had none of them discontinued, in a trial whose own authors report that a large number withdrew. This course is education, not medical advice, and amycretin is investigational, unapproved, and available only in a clinical trial.